Infinity Reports Phase 1 Data for IPI-145 at ACR/ARHP Supporting Development in Inflammatory Conditions

Loading...
Loading...
Infinity Pharmaceuticals
INFI
today announced new data from its completed Phase 1 study of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data showed that IPI-145 was well tolerated and demonstrated favorable pharmacokinetics following administration of single and multiple doses in healthy adult subjects. Infinity also presented data demonstrating the activity of IPI-145 in preclinical models of rheumatoid arthritis (RA). These findings were presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting held in Washington, DC. “These data show that IPI-145 is well tolerated in healthy subjects and inhibits immune cell activation even at low doses,” stated Vito J. Palombella, chief scientific officer at Infinity. “The profile of IPI-145 observed in this Phase 1 trial, combined with our preclinical studies in inflammation, support Phase 2 clinical development in patients with asthma and RA as well as other potential inflammatory indications.” The PI3Ks are a family of enzymes involved in multiple cellular functions, such as cell proliferation and survival, metabolism, cell differentiation and cellular trafficking.^1 PI3K-delta and -gamma, two isoforms of PI3K, are necessary for adaptive and innate immunity, and the role of these enzymes in various immune cells supports the development of IPI-145 for the treatment of inflammatory disorders as well as hematologic malignancies.^2 Infinity believes that IPI-145 is the only PI3K-delta and -gamma inhibitor currently in clinical development.
Loading...
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...